Solid Tumor Targeting CAR-T Development Service with Checkpoint Blockade

Creative Biolabs offers a comprehensive Solid Tumor Targeting CAR-T Development Service with Integrated Checkpoint Blockade to address exhaustion, limited persistence, and toxicity challenges in solid tumors. Our platform enables the engineering of cell-intrinsic checkpoint resistance through advanced strategies such as PD-1 dominant-negative receptors and CRISPR-mediated gene silencing, eliminating reliance on systemic checkpoint inhibitor infusions. By restoring durable effector function within the immunosuppressive tumor microenvironment, this service enhances therapeutic efficacy and safety. We provide end-to-end support, from construct design and cell engineering to functional validation and preclinical evaluation, helping advance robust CAR-T candidates capable of overcoming the barriers of solid malignancies.

Introduction

The clinical success of CAR-T therapy in liquid tumors has been hindered in solid tumors by the PD-1/PD-L1 axis, which induces T-cell anergy upon infiltration. Blocking these inhibitory pathways is essential for restoring effector functions such as IFN-gamma and Granzyme B secretion. The cell-intrinsic strategies, such as Dominant-Negative Receptors (DNR), outperform systemic antibody combinations in sustainability and tumor-limited specificity.

Fig.1 Inhibitory pathway blockade and T cell reactivation.¹

Service

Our service provides a comprehensive suite of solutions designed to transform conventional CAR-T candidates into "armored" therapies capable of surviving the hostile tumor microenvironment.

• Precision Engineering: We integrate checkpoint blockade directly into the CAR-T cell, eliminating the need for separate systemic antibody administration and reducing off-target immune-related adverse events.
• Enhanced T-Cell Persistence: Our platforms significantly delay T-cell senescence and exhaustion, ensuring that your CAR-T cells remain active for multiple rounds of tumor cell killing.
• Preclinical Validation: We offer robust in vitro exhaustion assays and orthotopic in vivo models to provide the data packages required for regulatory filings.
• Tailored Solutions: Whether your project targets Mesothelin, GD2, HER2, or EGFRvIII, we customize the checkpoint blockade strategy to fit your specific antigen and tumor type.

Discover How We Can Help - Request a Consultation.

Our Platform

We provide a multi-faceted technology platform for developing next-generation CAR-T therapies with integrated checkpoint inhibition:

• PD-1 Dominant-Negative Receptor (DNR) Platform: Engineering CAR-T cells to express a truncated PD-1 receptor that lacks signaling domains, acting as a "decoy" to saturate PD-L1 ligands.
• Gene Knockout: Targeted deletion of the PDCD1 gene to create natively checkpoint-resistant T-cells.
• Autocrine scFv Secretion (Armored CARs): Developing cells that locally secrete PD-1 or PD-L1 scFv antibodies directly into the TME.
• Chimeric Switch Receptors: Converting inhibitory PD-1 signals into internal costimulatory signals to further boost T-cell activation.

Workflow

Final Deliverables: Clients receive a Comprehensive Bioanalytical Report detailing all experimental parameters and results, the Engineered CAR-T Cell Product, and Preclinical Data Packages suitable.

Key Advantages

• Integrated Solid Tumor Strategy: Seamless integration of tumor-targeting CAR design with immune checkpoint modulation to address antigen heterogeneity and immunosuppressive tumor microenvironments.
• Flexible Checkpoint Engineering Options: Support for multiple checkpoint modulation approaches, including gene disruption, dominant-negative receptors, and autocrine secretion of checkpoint-blocking molecules.
• Mechanism-Driven Evaluation: Built-in assays to assess T-cell exhaustion, persistence, cytokine profiles, and resistance to checkpoint-mediated inhibition.
• Customizable and Scalable: Adaptable workflows to support early discovery, lead optimization, and preclinical development across diverse solid tumor indications.

FAQs

Partner with Us

We work closely with partners to design flexible, mechanism-focused development strategies that accelerate translational progress while maintaining scientific rigor. Whether you are exploring new targets, optimizing checkpoint-resistant CAR designs, or advancing a candidate toward preclinical readiness, we provide customized, transparent, and collaborative support at every stage. Please contact us to discuss the optimal strategy for your trial design.

Reference

1. Satapathy, Bibhu Prasad et al. “The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.” Frontiers in immunology vol. 15 1389971. 10 May. 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1389971